Prosecution Insights
Last updated: November 21, 2026
Application No. 17/767,783

COMPOSITIONS AND METHODS FOR DELIVERING NUCLEIC ACIDS TO CELLS

Final Rejection §103
Filed
Apr 08, 2022
Priority
Oct 10, 2019 — provisional 62/913,430 +2 more
Examiner
PURDY, KYLE A
Art Unit
1611
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
University of Maryland, Baltimore
OA Round
4 (Final)
41%
Grant Probability
Moderate
5-6
OA Rounds
0m
Est. Remaining
77%
With Interview

Examiner Intelligence

Grants 41% of resolved cases
41%
Career Allowance Rate
410 granted / 1004 resolved
-19.2% vs TC avg
Strong +36% interview lift
Without
With
+35.8%
Interview Lift
resolved cases with interview
Typical timeline
4y 1m
Avg Prosecution
80 currently pending
Career history
1094
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
62.8%
+22.8% vs TC avg
§102
13.8%
-26.2% vs TC avg
§112
14.3%
-25.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1004 resolved cases

Office Action

§103
DETAILED ACTION Status of Application The Examiner acknowledges receipt of the arguments filed on 9/24/2026. Claims 1-3, 6, 7, 9-14, 18-21, 27-29, 31, 33, 35, 53 and 54 are presented for examination on the merits. The following rejections are made. Response to Applicants’ Arguments Applicant’s arguments filed 9/24/2026 regarding the rejection of claims 1, 3, 6, 7, 13, 14, 18-21, 27-29, 31, 33, 53 and 54 made by the Examiner under 35 USC 103 over Kurosaki et al. (Biomaterials 30, 2009, 2846-2853) in view of Stephan et al. (US 11872195) and Na et al. (US 2015/0225723) have been fully considered but are not considered persuasive and are MAINTAINED for the reason of record in the Office Action mailed 3/24/2026. Applicant’s amendments filed 3/2/2025 overcome the rejection of claims 2, 9-12 and 35 made by the Examiner under 35 USC 103 over Kurosaki et al. (Biomaterials 30, 2009, 2846-2853) in view of Stephan et al. (US 11872195) and Na et al. (US 2015/0225723), further in view of Forrest et al. (Pharmaceutical Research, 21(2), 365-371) have been fully considered but are not considered persuasive and are MAINTAINED for the reason of record in the Office Action mailed 3/24/2026. In response to the 103 rejections, Applicant asserts the following: Na’s vectors utilize cationic polymers that help stabilize the negatively charged genes and facilitate delivery of said genes but leads to reduced gene delivery relative to gene delivery via viral vector and technological difficulty. Thus, Na disparages and teaches away from using non-viral polyplex particles comprising cationic polymer and anionic polymer as claimed; and The instant invention has found that the claimed ratio of N/P results in improved transfection which could not have been predicted from the broad range described by Na. In response to A, the Examiner acknowledges the above argument but is not persuaded. Na’s invention is to a nanocomposite material for delivering a gene. As observed by Applicant, the nanocomposite may include a cationic material. Na teaches that the inclusion of cationic material (e.g. polymer) stabilizes the genes by forming a complex through electrostatic interaction with the negatively charged genes and that the presence of the cationic material facilitates intracellular delivery (see [0004]). Regarding the downsides of including a cationic material, Na teaches that the cationic material however provides less efficiency delivery of genetic material than a viral vector and that the cationic material may cause acute toxicity. However, Na teaches that these shortcomings may be mitigated by forming a tertiary complex of a gene/cationic material composite and an anionic polymer which considerably gene delivery while being capable of lowering toxicity (see [0006]). The use of a cationic polymer for improving the delivery of genes within the complex while leading to reduced gene delivery and technological difficulty is not seen as a teaching away as the delivery mechanism would be well thought through and balanced so as to achieve a desirable and effective outcome. Moreover, given that the entire framework of Na is to deliver genetic material to a target by way of a non-viral delivery mechanism utilizing cationic materials, it is not clear how Na is teaching away from using a cationic material as alluded to by Applicant. A feature of Na’s invention is the use of cationic polymers. After all it is a feature of Na’s claims, e.g. see claim 1. In response to B, Applicant argues that Na’s N/P ratio of 0.1-100, and preferably from 0.1-50, is broad but is at present claiming a range of at least 15. The upper bound of both of Na’s ranges, (100 and 50) lie within Applicant’s claimed range of at least 15. Na teaches that the N/P ratio is important in facilitating gene stabilization thereby increasing cell absorption efficiency as well as for forming a stable gene nanocomposite (see [0040]). Thus, it would be reasonable to expect that the use of these ratios would provide such beneficial outcomes when applied to Kurosaki. Applicants Figure 2 appears to show that the variation in the presence of the PEI in the nanocomposite impacts the transfection efficiency as measured by %GFP for composites either in serum or free from serum. Fig 3A does not appear to show any relationship between N/P and transfections whereas Fig 3B appears to demonstrate that transfection correlates with N/P. data appears to effect appears to diminish as the amount of PEI increases above 15%. It is not clear to the Examiner what, if any, unexpected results could be gleaned from this data set. Of interest is Figure 5A which appears to show that the serum IP30-10 composite (N/P 30 and PEMA 10%) provides improved transfection serum relative to the serum-free sample. This effect is also observed in Figure 5B for the same complex. However, the feature of the nanocomposite comprising serum and 10% PEMA is not presently claimed but would likely be considered if incorporated into the claims. Maintained Rejections, of Record Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1, 3, 6, 7, 13, 14, 18-21, 27-29, 31, 33, 53 and 54 is/are rejected under 35 U.S.C. 103 as being unpatentable over Kurosaki et al. (Biomaterials 30, 2009, 2846-2853; of record) in view of Stephan et al. (US 11872195; filed 05/2017; of record) and Na et al. (US 2015/0225723; of record). Describes a complex of DNA, polyethyleneimine (PEI) and polyglutamic acid for gene delivery systems. The complex is made according to the following Figure: PNG media_image1.png 115 340 media_image1.png Greyscale (see Figure 1). It is observed that plasmid DNA is complexed with PEI wherein the pDNA/PEI complex is then treated with a polyanion (polyglutamic acid) so as to coat (envelop) the pDNA/PEI surface (see instant claims 1, 7, 27, 29, 31, 33. The PEI used in the complex is to be branched (see Section 2.1, page 2846) (see instant claim 3). The complex comprises a ratio of phosphate (of pDNA): nitrogen (of PEI) of 1:8. Kurosaki states that the DNA/PEI/polyglutamic acid complex is used in method of treating erythrocytes and melanoma cells so as to transfect the target cells with the complexed DNA (see sections 2.4, 2.5, page 2847) (see instant claims 53 and 54). Regarding claims 13 and 14, Kurosaki teaches that the concentration of the polyglutamic acid was directly related to the uptake of the complex in a concentration dependent manner (See page 2851). Moreover, the charge ratio of phosphate (of pDNA):nitrogen (of PEI):carboxylate (of the anion, polyglutamate) is 1:8:6 and as the charge ratio would be related to the weight ratio of the complex’s component materials, this ratio would suggest that the anionic polyglutamate is present in an amount of 40% ([6/15]*100). Thus, as a) the uptake of the complex is directly related to the presence of the polyglutamic acid and b) 40% of the complex charge/mass could be tired to the polyanion polyglutamic acid, the concentrations of instant claims 13 and 14 would have been obvious. It’s noted that 40% is above the upper range value of instant claim 14 but, as noted before, obviousness exists where claimed ranges are sufficiently close that one would reasonably expect similar properties. See MPEP 2144.05(I). Kurosaki fails to teach the inclusion of a targeting moiety that targets an immune cell, wherein the particle is internalized by the target cell by receptor mediated endocytosis. Stephan is directed to the targeted delivery of nucleic acids via nanocarriers. The nanocarrier includes agents that can facilitate internalization by and/or transfection such as PEI/DNA complexes (see column 11, lines 33-35 and lines 57-65). The nanocarrier may be modified to possess a coating so as to impart a negative surface charge. Exemplified coating materials include polyglutamic acid (see column 12, lines 40-42 and column 13, lines 1-5). The nanocarrier may comprise a binding domain so as to bind to a marker of a target cell so as to initiate rapid receptor-induced endocytosis so as to internalize the particle (see column 5, lines 28-65). Although endocytosis is taught by Stephan, such is related to how the product is used and is considered an intended use limitation. See MPEP 2111.02. The binding domain may be an antibody such is a single chain variable fragment antibody (scFv) (see column 22, lines 32-44 and claims 8-9) (see instant claims 18-21). The binding domain can be used to target immune cells (see column 7, liens 1-5) (see instant claim 1). Thus, it would have been obvious to modify Kurosaki’s particle such that the resulting particle comprised an antibody thereby enabling the modified particle to target specific desired cells. Kurosaki fails to teach the N/P ratio as being at least 15. Na, like Kurosaki, is directed to gene/cationic polymer complexes for delivering genetic material to a target cell. It is taught that the ion composite of the gene and cationic polymer is to have a N/P ratio of between 0.1-100, preferably from 0.1-50 and that complexes within said range facilitate gene stabilization thereby facilitating an increase in cell absorption efficiency and formation of stable gene nanocomposites (see [0040]). Thus, it would have been obvious to modify Kurosaki’s complex to modulate the N/P ratio to identify a ratio which best suited the stability and absorption efficiency and if such a manipulation found a N/P ratio exceeding 15, then such would have been the result of ordinary skill and common sense. See MPEP 2143(I)(A) which states that combining prior art elements according to known methods to yield predictable results is supportive of obviousness. Therefore, the invention as a whole is prima facie obvious to one of ordinary skill in the art at the time the invention was filed, as evidenced by the references, especially in absence of evidence to the contrary. Claims 2, 9-12 and 35 are rejected under 35 U.S.C. 103 as being unpatentable over Kurosaki et al. (Biomaterials 30, 2009, 2846-2853) in view of Stephan et al. (US 11872195; filed 05/2017; of record) and Na et al. (US 2015/0225723; of record) as applied to claims 1, 3, 6, 7, 13, 14, 18-21, 27-29, 31, 33, 53 and 54 above, and further in view of Forrest et al. (Pharmaceutical Research, 21(2), 365-371; of record). Kurosaki fails to teach the PEI as being acetylated. Forrest, like Kurosaki, is directed toward using PEI in the transfection of target cells. The PEI is taught to be a known delivery vector of nucleic acid and that modifying PEI to possess acetyl functionalities improves the delivery vectors properties. It is taught that PEI may be modified such that it is 27% acetylated (see abstract and Table 1) and that this acetylated PEI increases the transfection efficiency by 6-fold (see page 369). It would have been obvious to modify the PEI used in Kurosaki’s complex such that it was acetylated (25%), as taught by Forrest, so as to improve the transfection efficiency of the nucleic acid delivery complex. See MPEP 2143(I)(D) which states that it is obvious to apply a known technique (e.g. acetylate PEI) to a known product (e.g. PEI DNA complex) ready for improvement to yield predictable results (e.g. improved gene delivery). Therefore, the invention as a whole is prima facie obvious to one of ordinary skill in the art at the time the invention was filed, as evidenced by the references, especially in absence of evidence to the contrary. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to KYLE A PURDY whose telephone number is (571)270-3504. The examiner can normally be reached from 9AM to 5PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bethany Barham, can be reached on 571-272-6175. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). /KYLE A PURDY/Primary Examiner, Art Unit 1611
Read full office action

Prosecution Timeline

Show 1 earlier event
May 06, 2025
Non-Final Rejection mailed — §103
Sep 08, 2025
Response Filed
Oct 02, 2025
Final Rejection mailed — §103
Mar 02, 2026
Request for Continued Examination
Mar 09, 2026
Response after Non-Final Action
Mar 24, 2026
Non-Final Rejection mailed — §103
Sep 24, 2026
Response Filed
Oct 29, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799095
N-acetylserotonin Derivatives as TrkB Activators and Uses Thereof
4y 0m to grant Granted Nov 17, 2026
Patent 12797412
PHARMACEUTICAL COMPOSITION FOR IMPROVING HEALTH, CURE ABNORMALITIES AND DEGENERATIVE DISEASE, ACHIEVE ANTI-AGING EFFECT OF THERAPY AND THERAPEUTIC EFFECT ON MAMMALS AND METHOD THEREOF
2y 5m to grant Granted Nov 17, 2026
Patent 12788710
CUSTOMIZED COSMETIC COMPOSITIONS, AND METHODS OF REJUVENATING AND UTILIZING CONDITIONED MEDIA AND/OR COMPONENTS THEREOF
4y 1m to grant Granted Nov 10, 2026
Patent 12778134
COMPOSTABLE ANTI-MICROBIAL FILM AND METHOD OF APPLYING FILM TO PACKAGING
4y 2m to grant Granted Nov 03, 2026
Patent 12779008
PROCESS FOR PURIFICATION OF MITRAGYNINE
3y 6m to grant Granted Nov 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
41%
Grant Probability
77%
With Interview (+35.8%)
4y 1m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1004 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month